医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Menarini Group and MSD Extends Global Partnership to the Asia-Pacific Region

2016年06月09日 PM06:54
このエントリーをはてなブックマークに追加


 

SINGAPORE

Singapore-based A. Menarini Asia-Pacific Holdings Pte Ltd (“Menarini Asia-Pacific”) and MSD have embarked on a multi-year partnership for Menarini Asia-Pacific to assume the sales, marketing and distribution of a number of MSD’s pharmaceutical brands in Asia-Pacific since January 2016.

The partnership involves six (6) countries, namely Malaysia, Singapore, Philippines, Hong Kong, Brunei and Macao with annual sales in excess of USD70 million1 that could potentially extend to other key Asia-Pacific markets. The partnership covers a portfolio of highly recognized brands among physicians and patients, ranging from Cardiology, Respiratory and Women’s Health to Central Nervous System and Dermatology. Prior to this agreement, Menarini and MSD had already developed similar partnerships in several other markets in Europe.

“Menarini is excited about the extended partnership to the Asia-Pacific Region that will serve to further strengthen our global collaboration with MSD. MSD is a partner that shares the same core values of upholding a culture of integrity and maintaining the highest ethical standards in the way we do business. The MSD portfolio both complements our existing brands and expands our therapeutic categories and, thanks also to our extensive presence and capabilities in the Region, I am confident that that it will allow us to speed up our growth, said Dr. Luca Lastrucci, CEO of Menarini Asia-Pacific.

“Menarini has been a reliable partner for MSD with similar shared values, a strong sales and marketing footprint, and an excellent track record across the region. We are confident they will grow these brands and increase access for patients to these important medicines,” said Jan Van Acker, President, MSD Asia-Pacific.

About Menarini Asia-Pacific

Menarini Asia-Pacific is a member of the Menarini Group, the world’s largest Italian biopharmaceutical company, and provides physicians and healthcare professionals with medical and scientific information with competence, correctness and the highest ethical standards in all its work processes”. Menarini has the heritage of over 130 years and over 16,000 employees in more than 100 countries. Menarini Asia-Pacific’s vision is to be a leading provider of important healthcare brands to improve the lives of people in the region. Menarini Asia-Pacific operates across the entire commercial value chain, from clinical development, regulatory approval and product launch to lifecycle management with a diverse portfolio of proprietary and partnered brands in key therapeutic fields, including Consumer Health, Dermatology, Allergy/Respiratory, Cardiovascular, Oncology/Specialty Care and Men’s Health.

For more information about Menarini Asia-Pacific, please visit: www.menariniapac.com

1 IMS MIDAS MAT Q4 2015

View source version on businesswire.com: http://www.businesswire.com/news/home/20160609005549/en/

CONTACT

For A. Menarini Asia-Pacific Holdings Pte Ltd:
Jennifer Lin,
+65-64943427
Senior Regional Corporate Branding & Communications
Manager
JenniferCW.lin@menariniapac.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • CANbridge Life Sciences Receives Approval to Commence CAN017 Ib/III Trial in Esophageal Squamous Cell Cancer (ESCC) In China
  • AVEO Announces Acceptance of CANbridge Investigational New Drug Application for CAN017 (AV-203) Trial in Esophageal Squamous Cell Cancer (ESCC) in China
  • STAAR Surgical and Shinjuku LASIK Clinic in Japan Announce Strategic Cooperation Agreement
  • 新研究调查诊断性多通道睡眠检查之前采用Masimo SET®脉搏氧饱和度仪居家监测筛查唐氏综合征患儿罹患阻塞性睡眠呼吸暂停的风险
  • ダウン症候群の小児を対象とする睡眠時障害診断のマルチチャンネル研究に先立つ閉塞性睡眠時無呼吸症リスクのスクリーニングとしてMasimo SET®パルスオキシメトリーを使用するホームモニタリングの有用性を検討する新研究